The U.K.'s Consort Medical has closed its $374 million buyout of contract drug developer Aesica, part of an effort to diversify its offerings and expand the market for its proprietary drug delivery devices.
Pharma outsourcer Recipharm has acquired a Portuguese contract drug developer for €112.3 million ($140 million) in cash and stock, bolstering its global scale and further consolidating the world of R&D service providers.
Parexel International has cut the ribbon on a new clinical trial supply hub in Europe, centralizing the CRO's continental logistics services as part of a companywide effort to more efficiently conduct studies around the globe.
Catalent has acquired another R&D tech firm, snapping up Micron Technologies and its particle sizing capabilities as the recently IPO'd company works to expand its share of the drug development market.
Chinese CRO WuXi PharmaTech is forecasting a better-than-expected 2014 after a strong third quarter and some timely deals, moving into the new year with hopes for continued global growth.
Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.
Indian CRO GVK Biosciences is expanding its capacity in early-phase R&D, buying a local preclinical testing outfit as it works to expand its reach.
Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.
PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.
Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.
Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.
CRO conglomerate PRA is angling to be the next contract drug developer to make a splash on Wall Street, setting terms for a $400 million IPO.
Baltimore CRO Paragon Bioservices has raised a $13 million A round, money it'll spend to stretch out its offerings in biologics R&D and manufacturing.
Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.
Quintiles, the world's largest CRO, is rolling toward its biggest year yet on the heels of a fourth straight quarter with more than $1 billion in sales.
SRI International's in-house CRO has opened up a new Phase I center, expanding its footprint in the market for early-stage research.
CRO inVentiv Health is dumping out its own trial document storage system and replacing it with Veeva Systems' cloud-based platform, a move the eClinical provider touts as a major affirmation of its technology.
MPI Research has acquired fellow Michigan CRO Jasper Clinical Research and Development for an undisclosed sum, a move that will augment the company's offerings in Phase I trials.
The Association of Clinical Research Organizations, which represents the world's largest CROs, is putting together a sort of contractors' council to weigh in on the efforts of TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.